C4x Discovery Investors - C4XD

C4x Discovery Investors - C4XD

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
C4x Discovery Holdings Plc C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 41.50 15:40:50
Open Price Low Price High Price Close Price Previous Close
41.50 41.50 43.00 41.50 41.50
more quote information »
Industry Sector

Top Investor Posts

alloa2003: New board appointment which to be fair is just what the doctor ordered:- "20 April 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect. Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies. Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017. Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals. During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee. Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations. He also received the Lilly, Chairman's Ovation Award 2004 for outstanding achievement to Lilly. Eva-Lotta Allan, Chairman of C4X Discovery, said: "Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based. His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior. We welcome Simon to the Board and look forward to working closely with him." Simon Harford, incoming Non-Executive Director, added: "I am delighted to be joining the C4XD Board at this stage of the Company's development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company's technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value."
astorcourt: Clive has a video out today on the proactive investors site
alloa2003: Not sure what the attitude is all about? Firstly I presume we have all realised that todays deal was announced in Euros so when converted into dollars, like the Indivior deal, is a potential $571m. So it is approaching double the potential income of the first, huge, deal. The facts are the management of C4XD were tarnished when the first fund raising went wrong. They failed to agree a concrete price which then halved overnight and the troubles began. The fact the company is listed on AIM didnt help - not the best reputation. However, credit where it is due, the management have brought in influential private and institutional investors. Appears to me, assuming just one deal comes off, it is fully funded for a long long time. The shares have more than doubled recently, so news was probably leaking about short to medium term prospects. Like it or not, institutional (and large PIs) investors would not have poured millions into this company, even at rock bottom prices, if they didnt know more than we did. As of today we have two deals signed which could bring in a maximum of $865m in years to come. There is another partnership deal which seemed to be further down the road which has not yet been announced/agreed. There are also other molecules in the pipeline and no doubt more will emerge in the future. There have been upfront payments alread but its interesting that:- - The Indiviour deal is in the middle of clinical trials (so far so good) - Todays deal involves a VERY VERY early stage payment which suggests there was competition to get involved in this one So, egos aside, the management are:- - rebuilding their reputation - deals are finally being signed - potentially a lot more and maybe bigger ones in the pipeline Upfront payments, including todays are circa $20m, so thats leaves potential income streams going forward which could bring in another $845m. The company is capped at circa $124m which leaves potential for huge upside if only one of these products comes to market. Then we have the others in the deal pipeline, one nearing partner stage, and others in the future (both being worked on and not yet discovered). So all in all, while we need one treatment to be appoved for the final rubber stamping of the company, there is potentially HUGE upside. Not without risks, DYOR
jev1: Not all investors work off your impatience on a day trade or a one hour trade. It often tales time for news to be digested and reported in the wider media.
davemac3: It may have been a 3-4 month window for the large investors. Why did the price double on no news?
amaretto1: Very few private investors in ...Institutions walking it up..Probably polar Good for you holders.
alloa2003: Emailed C4XD today. Lets see if I get a reply:- I am an investor in C4XD and have been since the heady days when the shares were 50p+. During the last 12 months we have seen numerous fund raisings which have diluted private investors with the constant promise these funds will result in a stronger business. So far we have had next to no updates on existing treatments let alone any new ones, we have heard endless promises that partnership deals are in the offing but absolutely nothing to report. As a concept I believe strongly in this company but your PR skills are atrocious and the only winners lately have been the institutions taking on cheap stock at our expense. When can we expect any meaningful updates? When can we expect to see progress? I notice that Mr Dix is involved in a government Covid research project. At the moment it looks as though this is to the severe detriment of the company. If that is the case, you need to find a replacement asap to push the company along. A company that has raised a relatively huge amount of money lately which is disappearing each month with, so far, absolutely nothing to show for it. Unless results are forthcoming, I very much doubt the market will accept another fund raising even at the hugely dilutive levels which seem to have become the norm with C4XD.
amaretto1: They are in the market .. trying to sell the story to investors.Why not let the 14p shares go to private investors ....Who have gone through years of agony and pain.I'd buy back in at 14penceAnd hold next year ....
alloa2003: There are obviously things going on behind the scenes and those who invested in the recent fund raising will be aware of confidential information. However, it is about time we as long term shareholders were also made privy to what is going on. Yes, we know about commercial agreements etc but the fund raising in October last year was supposed to (among other things) strengthen the company's negotiating position with the big players. However, since then we have heard nothing about developments, new deals, etc which are obviously being discussed behind the scenes. We are expected to keep on taking a hit with dilution, which I dont mind if there is something at the end of it. The company needs to be more open with private investors and not just institutional investors. For the record I think the potential for this company is huge and the INDV money and another deal would probably push it towards being self financing going forward with huge cashflow.
the stigologist: Indivior to Announce 2020 Year-to-Date and Q3 Results October 29th Slough, UK, and Richmond, VA, 15 October 2020 - Indivior PLC (LON: INDV) today announced that it will release its 2020 year-to-date and third quarter results on Thursday, October 29th at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the Company's website at www.indivior.com . Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 29th.
ADVFN Advertorial
Your Recent History
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210510 19:08:55